About Karbinal ER
Karbinal ER was established in 2011 in Chesterfield, United States. Operations are centered on a website that delivers detailed information about allergy medications. The platform serves the healthcare information sector by offering resources on drug usage, side effects, and related treatments. Content is tailored for users seeking reliable data on allergy management. No physical products are distributed; focus remains on digital accessibility for educational purposes.
- Headquarter Chesterfield, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Karbinal ER
Detailed funding history for Karbinal ER
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Karbinal ER
Karbinal ER has secured backing from 1 investor. Prominent investors backing the company include Cerecor.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapeutics for immunological and neurological disorders are developed.
|
Locked | Locked | Locked |
Investor details for Karbinal ER
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Karbinal ER
Investment portfolio details for Karbinal ER
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Karbinal ER
Detailed financials for Karbinal ER
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Karbinal Er Comparisons
Peer comparison for Karbinal ER
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Karbinal ER
Detailed competitors of Karbinal ER
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Karbinal Er
Complete news archive for Karbinal ER
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Karbinal ER
Karbinal ER was founded in 2011.
Karbinal ER is headquartered in Chesterfield, United States. It is registered at Chesterfield, Missouri, United States.
Karbinal ER was established in 2011 in Chesterfield, United States. Operations are centered on a website that delivers detailed information about allergy medications. The platform serves the healthcare information sector by offering resources on drug usage, side effects, and related treatments. Content is tailored for users seeking reliable data on allergy management. No physical products are distributed; focus remains on digital accessibility for educational purposes.
Karbinal ER has 1 investor. Key investors include Cerecor.